ArticleHuman mutation2013
Investigation of the relationship between prostate cancer and MSMB and NCOA4 genetic variants and protein expression.
Article in Human mutation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants.Nature communications · 2018Pooled it
- Pooled it
- Identification of novel protein markers and therapeutic targets for common urological cancers by integrating large-scale human plasma proteome with the genome.Scientific reports · 2026Article
- Race and Sex Differences in PRMT6 Expression in Lung Tumors in Relation to Neighborhood Violence.Cancer prevention research (Philadelphia, Pa.) · 2025Article
- Machine Learning for Digital Scoring of PRMT6 in Immunohistochemical Labeled Lung Cancer.Cancers · 2023Article
- Ferroptosis and Its Multifaceted Role in Cancer: Mechanisms and Therapeutic Approach.Antioxidants (Basel, Switzerland) · 2022Review
- Roles of ferroptosis in urologic malignancies.Cancer cell international · 2021Review
- Article
- Article
- Contribution ofOncotarget · 2019Article
- Article
- Quantitative comparison and reproducibility of pathologist scoring and digital image analysis of estrogen receptor β2 immunohistochemistry in prostate cancer.Diagnostic pathology · 2016Article
- Prostate Cancer Expression Profiles of Cytoplasmic ERβ1 and Nuclear ERβ2 are Associated with Poor Outcomes following Radical Prostatectomy.The Journal of urology · 2016Article
- Overexpression and purification of folded domain of prostate cancer related proteins MSMB and PSA.Molecular biology reports · 2016Article
- Novel binders derived from an albumin-binding domain scaffold targeting human prostate secretory protein 94 (PSP94).Protein & cell · 2015Article
- Prostate Cancer Genetics: A Review.EJIFCC · 2015Article
- MSMB variation and prostate cancer risk: clues towards a possible fungal etiology.The Prostate · 2014Review
- MSMB gene variant alters the association between prostate cancer and number of sexual partners.The Prostate · 2013Article
- Genome-wide association studies on prostate cancer: the end or the beginning?Protein & cell · 2013Review
- Current status of biomarkers for prostate cancer.International journal of molecular sciences · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 2 countries.
Funding
Abstract
Two genome-wide association studies (GWAS) identified the β-microseminoprotein (MSMB) promoter SNP, rs10993994:C>T, as significantly associated with prostate cancer (PC) risk. Follow-up studies demonstrate that the variant allele directly affects expression of the MSMB-encoded protein, PSP94, and also suggest that it affects mRNA expression levels of an adjacent gene, NCOA4, which is involved in androgen receptor transactivation. In a population-based study of 1,323 cases and 1,268 age-matched controls, we found the NCOA4 SNP, rs7350420:T>C, was associated with a 15% reduction in PC risk, but the association was not significant after adjustment for the rs10993994:C>T genotype. Tumor tissue microarrays of 519 radical prostatectomy patients were used to measure PSP94 and NCOA4 protein expression. Taken together, these data confirm that the rs10993994:C>T variant allele is associated with decreased PSP94 expression, and the association is stronger in tumor compared to normal prostate tissue. No association was observed between rs10993994:C>T and NCOA4 expression, and only moderate associations were seen between two NCOA4 SNPs, rs10761618:T>C and rs7085433:G>A, and NCOA4 protein expression. These data indicate that the increase in PC risk associated with rs10993994:C>T is likely mediated by the variant's effect on PSP94 expression; however, this effect does not extend to NCOA4 in the data presented here.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.